\"The real motivation here is actually exfiltrating intellectual property and getting a competitive advantage over Indian pharmaceutical companies,\" says Cyfirma Chief Executive Kumar Ritesh

China has given conditional approval for a single dose COVID-19 vaccine, touted to be a rival to Johnson & Johnson's one-jab shot cleared by the US drug regulator

The Food and Drug Administration is expected to quickly follow the recommendation and make J&J's shot the third vaccine authorised for emergency use in the US

Data analysed by Public Health England (PHE) showed the Pfizer provided high levels of protection against infection and symptomatic disease from a single dose

Pfizer has shipped around 40 million doses to locations across the United States so far and is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer's chief business officer

Symptoms, as reported in clinical trials for the AstraZeneca shot, can include a high temperature or headache and are a normal sign that the body is generating an immune response

Phil Dormitzer, one of Pfizer's top viral vaccine scientists, said in an interview that he believes the current vaccine is highly likely to still protect against the concerning variant first discovered in South Africa

South African variant could significantly reduce vaccine protection, says Pfizer A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer-BioNTech vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday. Companies are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed. COV...

Pfizer and BioNTech said they were doing similar lab work to understand whether their vaccine is effective against another variant first found in Brazil

South Korea had said it would complete vaccinations on 1.3 million people by the first quarter of this year with AstraZeneca shots, but it slashed the target sharply to 750,000

In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data

WHO highlighted the need to reduce virus circulation and prevent infections so that it reduces the opportunities for coronavirus to mutate further.

Coronavirus vaccine: Sarah Gilbert, professor of vaccinology at Oxford told BBC that the researchers have already started working on the first part of the manufacturing process

Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75%, researchers said

Andrew Pollard of Oxford University, which helped develop the AstraZeneca vaccine, says the shot also appears to reduce the amount of virus in people infected with COVID-19

Coronavirus vaccine: Pfizer was the first pharmaceutical company to seek EUA from Drugs Controller General of India (DCGI) after its vaccine was approved in the UK and Bahrain

Coronavirus vaccine: India will get the maximum share of 97,164,000 doses (97.1 million), in addition to the direct orders placed by the Indian government with SII and Bharat Biotech

The yet-to-be peer-reviewed study, posted in the preprint repository medRxiv, assessed the antibody responses in 109 individuals with and without documented pre-existing immunity to the novel coronavirus

The British researchers behind the trial said data on vaccinating people with the two different types of coronavirus vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world

Vaccines are not yet approved for children, but testing already is underway for those as young as 12